Axsome Therapeutics, Inc.
LSE: 0HKF.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Herriot Tabuteau
- Employees
- 712
- Headquarters
- New York City, United States
- IPO year
- 2018
- Market cap
- $11.0B
- Website
- https://www.axsome.com
Loading 0HKF…
Loading profile data…Frequently asked questions about 0HKF
What does Axsome Therapeutics, Inc. (0HKF.L) do?
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
Where does 0HKF.L trade?
Axsome Therapeutics, Inc. (0HKF.L) trades on the London Stock Exchange.
What sector is 0HKF.L in?
Axsome Therapeutics, Inc. (0HKF.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Axsome Therapeutics, Inc.?
Herriot Tabuteau is the chief executive officer of Axsome Therapeutics, Inc. (0HKF.L).
Where is Axsome Therapeutics, Inc. headquartered?
Axsome Therapeutics, Inc. is headquartered in United States.
Does 0HKF.L pay a dividend?
Axsome Therapeutics, Inc. (0HKF.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HKF.L go public?
Axsome Therapeutics, Inc. (0HKF.L) completed its initial public offering in 2018.